The market has been flat over the last week, but is up 18% over the past year, with earnings forecast to grow by 15% annually. For investors willing to explore beyond well-known stocks, penny stocks—often smaller or newer companies—can offer intriguing opportunities. Despite being a somewhat outdated term, these stocks remain relevant for those seeking growth potential at lower price points and can be particularly appealing when backed by strong financials.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| ATRenew (RERE) | $3.37 | $810.62M | ✅ 3 ⚠️ 1 View Analysis > |
| Waterdrop (WDH) | $1.98 | $658.23M | ✅ 4 ⚠️ 0 View Analysis > |
| CuriosityStream (CURI) | $4.55 | $268.34M | ✅ 3 ⚠️ 3 View Analysis > |
| WM Technology (MAPS) | $0.951 | $164.19M | ✅ 4 ⚠️ 1 View Analysis > |
| Perfect (PERF) | $2.48 | $259.71M | ✅ 3 ⚠️ 0 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $100.75M | ✅ 3 ⚠️ 1 View Analysis > |
| Cardno (COLD.F) | $0.1701 | $6.64M | ✅ 2 ⚠️ 4 View Analysis > |
| BAB (BABB) | $0.886 | $6.1M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.72 | $109.16M | ✅ 3 ⚠️ 2 View Analysis > |
| Tandy Leather Factory (TLF) | $3.47 | $29.28M | ✅ 2 ⚠️ 2 View Analysis > |
Click here to see the full list of 412 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Atea Pharmaceuticals (AVIR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics for serious viral infections, with a market cap of $298.67 million.
Operations: Atea Pharmaceuticals, Inc. has not reported any revenue segments.
Market Cap: $298.67M
Atea Pharmaceuticals, Inc., with a market cap of US$298.67 million, is currently pre-revenue and unprofitable, yet it holds potential in the penny stock realm due to its promising pipeline. The company recently initiated a global Phase 3 trial for its hepatitis C treatment regimen following robust Phase 2 results showing high efficacy rates. Despite no significant revenue streams and forecasted earnings decline over the next three years, Atea's strong cash position—sufficient for over three years without dilution—and experienced management provide stability as it advances its clinical trials.
- Navigate through the intricacies of Atea Pharmaceuticals with our comprehensive balance sheet health report here.
- Evaluate Atea Pharmaceuticals' prospects by accessing our earnings growth report.
SmartRent (SMRT)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: SmartRent, Inc. is an enterprise real estate technology company offering management software and applications to rental property stakeholders globally, with a market cap of $201.35 million.
Operations: The company's revenue is primarily generated from its Electronic Security Devices segment, which accounts for $165.74 million.
Market Cap: $201.35M
SmartRent, Inc., with a market cap of US$201.35 million, faces challenges typical of penny stocks, including a recent NYSE delisting notice due to its share price falling below US$1.00. Despite this, the company has no debt and maintains sufficient cash runway for over three years if free cash flow continues growing historically. Recent leadership changes with experienced executives like Frank Martell aim to enhance operational efficiency and shareholder value through data-driven innovation. The introduction of AI-powered tools in its platform could further optimize property management operations and support ESG goals amid ongoing financial losses and goodwill impairments.
- Get an in-depth perspective on SmartRent's performance by reading our balance sheet health report here.
- Learn about SmartRent's future growth trajectory here.
Valens Semiconductor (VLN)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Valens Semiconductor Ltd. develops semiconductor products for the audio-video and automotive industries across various global markets, with a market cap of approximately $304.19 million.
Operations: The company's revenue is divided into two segments: Automotive, generating $22.26 million, and Cross Industry Business (CIB), contributing $40.87 million.
Market Cap: $304.19M
Valens Semiconductor, with a market cap of US$304.19 million, operates debt-free and maintains a cash runway exceeding three years based on current free cash flow. Despite its unprofitability and negative return on equity of -27.1%, the company has reduced losses over five years by 7.3% annually and forecasts revenue growth at 24.71% per year. Recent developments include Valens' chipsets being integral to D3 Embedded's new MIPI A-PHY platform, potentially enhancing connectivity in embedded vision systems. Leadership stability is expected with CEO Gideon Ben Zvi retiring post-2025 after achieving key milestones, ensuring continued strategic direction from the board.
- Jump into the full analysis health report here for a deeper understanding of Valens Semiconductor.
- Explore Valens Semiconductor's analyst forecasts in our growth report.
Next Steps
- Reveal the 412 hidden gems among our US Penny Stocks screener with a single click here.
- Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Atea Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com